GlassScriptPhysician profile
Jeneen Hinkle
NPI 1154798841
$3,078.63
in general payments reported to CMS, 2019-2025
33 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $670 · 2024: $604 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Education: $77.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.79 |
| Education | $77.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $439.05 | 2023-2025 | Tysabri, Vumerity, Skyclarys |
| Tg Therapeutics, INC. | $354.37 | 2023-2025 | |
| Genentech USA, INC. | $310.48 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Emd Serono, INC. | $270.89 | 2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $196.14 | 2023-2025 | |
| Celgene Corporation | $154.54 | 2023-2025 | Zeposia |
| Argenx US, INC. | $151.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $140.43 | 2023-2025 | Ultomiris, Soliris, Koselugo |
| Vanda Pharmaceuticals INC. | $140.07 | 2024-2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $126.03 | 2025 | Hyqvia |
| Ucb, INC. | $123.51 | 2023-2025 | Rystiggo, Fintepla, Nayzilam |
| Abbvie INC. | $106.13 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $77.36 | 2022 | |
| Tanabe Pharma America, INC. | $72.79 | 2024-2025 | Radicava |
| Pfizer INC. | $38.96 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $30.15 | 2024 | Acthar |
| Lundbeck LLC | $29.12 | 2025 | Vyepti |
| Pyros Pharmaceuticals, INC. | $28.02 | 2024 | Vigpoder |
| Alnylam Pharmaceuticals INC. | $27.77 | 2025 | Onpattro |
| Upsher-Smith Laboratories LLC | $26.54 | 2025 | |
| Acadia Pharmaceuticals INC | $24.46 | 2025 | Daybue |
| Novo Nordisk INC | $24.23 | 2023 | |
| Jazz Pharmaceuticals INC. | $21.97 | 2025 | |
| Hospira, INC. | $19.47 | 2024 | |
| Aucta Pharmaceuticals, INC. | $19.34 | 2025 | Motpoly Xr |
| Boston Scientific Corporation | $18.94 | 2024 | |
| Genzyme Corporation | $18.12 | 2025 | |
| Lilly USA, LLC | $17.98 | 2023 | Amyvid |
| Averitas Pharma INC. | $16.58 | 2025 | Qutenza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.39 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $13.20 | 2024 | Ingrezza |
| Allergan, INC. | $11.95 | 2022 | |
| Sk Life Science, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeneen Hinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.